Aurora:离子通道(药物开发)联盟成立

 Aurora Biomed
    Aurora公司是全球科研方案设计开发方面的领头企业。我司产品及技术覆盖生命科学、环境科学、药品研究与安全监控，以及化学元素分析研究等多个领域，集研发与生产于一体，连科研与应用于一线。我们以提高人与环境的健康状况为使命，提供高通量并且高质、精确、精准的科学技术与服务。Aurora公司专注于药物研发方面的离子通道筛选技术以及创新高通量离子通道筛选技术，其专利的离子通道阅读器为制药业在研发初期发现并关注药品安全因素提供了可能性。除此以外，Aurora公司还乐意提供离子通道，通道蛋白和病毒，突变基因离子通道的设立和检测，和各种细胞株离子通道方面的合同研究服务。

Specs
    Specs公司是一家为生命科学行业的药物开发提供化学解决方案的著名供应商。该公司主营业务是为大研究项目提供各类高品质的合成药物，以进行高通量筛选，现场或非现场的药物处理，化学信息学处理及合同研究等应用。Specs公司拥有国家最先进的技术和世界一流的专家，为客户提供个性化服务，并为全球制药、生物技术和农药行业提供具有突破性的解决方案，让研究者将宝贵的时间和精力投入到更有创造性的工作中。详细信息请浏览www.specs.net

Alion Pharmaceuticals
    Alion公司已经开发了特有的硅片技术，可迅速地识别靶标化合物来调节某些离子通道和蛋白质的相互作用。该公司的技术适用于针对特殊离子通道设计小分子靶向药物，缩小了筛选范围，而那些有价值的化合物通过少量试验则可用离子通道定性。Alion公司的技术还适用于针对已知的目标物设计只知道多肽（蛋白质）结构的小分子靶向药物。
 

 

Vancouver, British Columbia, February 14, 2012

Aurora Biomed Inc. is pleased to announce that it has signed an agreement with Alion Pharmaceuticals and Specs to form a new Ion Channel Consortium that will provide a novel, comprehensive solution for ion channel drug discovery. Together, the three companies will offer value added identification and validation of ion channel modulators. The Ion Channel Consortium combines Alion’s proprietary method for short-listing drug candidates, Specs’ reliable sourcing and synthesis of compounds, and Aurora’s superior patch clamp services. Researchers now have an option that enables time and cost savings while providing a unique method to identify new drug candidates for channel opathies.

About Aurora Biomed
Aurora Biomed is a global leader in the design and development of laboratory solutions for life science, environmental science, drug discovery/safety and chemical analysis research. We are committed to improving the quality of human and environmental health by providing technology and services which facilitate a higher sample throughput while improving quality, accuracy and precision. Aurora Biomed focuses on ion channel screening services for drug discovery and innovative high-throughput ion channel screening technology. Aurora’s proprietary ion channel readers enable the pharmaceutical industry to address drug safety issues earlier in the discovery process. Aurora Biomed provides contract research services for ion channels, channel forming proteins and toxins, creation and testing of mutant cDNA ion channels, and various ion channel cell lines.

About Specs
Specs is one of the world's leading suppliers of chemistry solutions for drug discovery to the Life Science industry. The main activities of Specs are focused on the supply of large numbers of high-quality screening compounds for High Throughput Screening (HTS), on-site and/or off-site compound handling, cheminformatics and contract research for lead discovery programs. Equipped with state-of-the-art technology and world-class expertise, Specs provides custom-tailored services and breakthrough solutions for the pharmaceutical, biotech and agrochemical industry worldwide, allowing the customers to concentrate on the development of their core (research) activities. Information about Specs can be found at www.specs.net

About Alion Pharmaceuticals
Alion has developed proprietary in silico technology to rapidly identify lead compounds to modulate certain ion channels and protein-protein interactions. The technology is applicable to designing small molecule leads for specific ion channels. Short-listed, high value compounds can then have their effect on ion channels characterized through limited experimentation. Alion’s technology is applicable to designing small molecule leads to a given macro-molecule target, where only the structure of a peptide (or protein) ligand is known.